

RESEARCH ARTICLE

Uncomplicated Clinical Malaria Features, the Efficacy of Artesunate-Amodiaquine and Their Relation with Multiplicity of Infection in the Democratic Republic of Congo

Hypolite Muhindo Mavoko^{1,2*}, Marion Kalabuanga³, Christopher Delgado-Ratto², Vivi Maketa^{1,2}, Rodin Mukele¹, Blaise Fungula³, Raquel Inocência da Luz², Anna Rosanas-Urgell⁴, Pascal Lutumba¹, Jean-Pierre Van geertruyden²

1 Tropical Medicine Department, Faculty of Medicine, University of Kinshasa, Kinshasa, Democratic Republic of Congo, **2** Global Health Institute, University of Antwerp, Antwerp, Belgium, **3** Outpatients Department, Lisungi Health Center, Kinshasa, Democratic Republic of Congo, **4** Institute of Tropical Medicine, Antwerp, Belgium

* mavoko@yahoo.com



OPEN ACCESS

Citation: Muhindo Mavoko H, Kalabuanga M, Delgado-Ratto C, Maketa V, Mukele R, Fungula B, et al. (2016) Uncomplicated Clinical Malaria Features, the Efficacy of Artesunate-Amodiaquine and Their Relation with Multiplicity of Infection in the Democratic Republic of Congo. PLoS ONE 11(6): e0157074. doi:10.1371/journal.pone.0157074

Editor: Aric Gregson, University of California Los Angeles, UNITED STATES

Received: October 16, 2015

Accepted: May 24, 2016

Published: June 9, 2016

Copyright: © 2016 Muhindo Mavoko et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Data Availability Statement: All data files are available from www.figshare.com, DOI: [10.6084/m9.figshare.3278932](https://doi.org/10.6084/m9.figshare.3278932). The files are entitled "Uncomplicated malaria features and efficacy of ASAQ in DR Congo" and "Multiplicity of infection_pre RCT Quinact_DR Congo."

Funding: This work was funded by Fonds Wetenschappelijk Onderzoek (FWO, Grant reference G.078.11 to JPVg), Vlaamse Interuniversitaire Raad—Universitaire Ontwikkelings Samenwerking (VLIR-UOS, Grant reference ZRDC2012MP076 to JPVg,

Abstract

Background

In the Democratic Republic of Congo, artesunate-amodiaquine (ASAQ) is the first-line medication recommended for uncomplicated malaria treatment. We conducted a study in Kinshasa to describe the clinical features of the disease and assess the efficacy of ASAQ and its impact on the multiplicity of infection in children with uncomplicated malaria.

Methods

Children aged 12 to 59 months with uncomplicated *P. falciparum* malaria were treated with ASAQ and followed up passively for 42 days. To distinguish new infections from recrudescing parasites, samples were genotyped using a stepwise strategy with three molecular markers (GLURP, MSP2 and MSP1). We then assessed PCR-corrected and -uncorrected day-42 cure rates and multiplicity of infection (MOI).

Results

In total, 2,796 patients were screened and 865 enrolled in the study. Clinical features were characterized by history of fever (100%), coryza (59.9%) and weakness (59.4%). The crude and PCR-corrected efficacies of ASAQ were 55.3% (95%CI: 51.8–58.8) and 92.8% (95% CI: 91.0–94.6) respectively, as 83.6% (95%CI: 79.1–87.2) of the recurrences were new infections. Compared to monoclonal infections, polyclonal infections were more frequent at enrollment (88.1%) and in recurrences (80.1%; $p = 0.005$; OR: 1.8, 95%CI: 1.20–2.8). The median MOI at enrollment (MOI = 3.7; IQR: 0.7–6.7) decreased to 3 (IQR: 1–5) in the recurrent samples ($p < 0.001$). Patients infected with a single haplotype on day 0 had no

PL), European and Developing Countries Clinical Trials Partnership (EDCTP, Grant reference MS.2010.10800.004 to JPVg) and the Belgian Technical Cooperation—Programme d'Etudes et d'Expertises—in the Democratic Republic of Congo (BTC, Grant reference FEE/06/12 to PL). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: The authors have declared that no competing interests exist.

recrudescence; the risk of recrudescence increased by 28% with each additional haplotype (HR: 1.3, 95%CI: 1.24–1.44).

Conclusion

The PCR-corrected efficacy of ASAQ at day 42 was 92.8%, but crude efficacy was relatively poor due to high reinfection rates. Treatment outcomes were positively correlated with MOI. Continued monitoring of the efficacy of ACTs—ASAQ, in this case—is paramount.

Trial Registration

ClinicalTrials.gov [NCT01374581](https://clinicaltrials.gov/ct2/show/study/NCT01374581)

Introduction

The Democratic Republic of Congo (DR Congo) is considered to be one of the countries most severely affected by malaria [1]. Malaria is endemic all over the country and transmission is stable in almost all areas [2]. Due to widespread chloroquine resistance, the Congolese National Malaria Control Program (NMCP) introduced sulfadoxine-pyrimethamine (SP) in 2001 as the first-line drug for uncomplicated malaria. After observing an increase in treatment failure rates with SP, the NMCP turned to artemisinin-based combination therapy (ACT) in 2005, in particular artesunate-amodiaquine (ASAQ), to replace SP. Artemisinin derivatives are known to act quickly and have a short half-life, and they are now being combined with a longer-acting partner drug which also plays a prophylactic role [3]. The synergistic action of the two drugs is expected to halt the emergence of resistance [4]. In 2010, the NMCP selected artemether-lumefantrine (AL) as an alternative first-line treatment, alongside ASAQ [5]. However, the availability of AL remains limited in the public sector [6]. Oral quinine was to be used as a rescue treatment in combination with an antibiotic that has antiparasitodal properties (tetracycline, doxycycline or clindamycin), according to the latest guidelines [5].

Monitoring the efficacy of ACTs is essential, especially since the reported emergence of resistance to artemisinin derivatives in Southeast Asia [3,7,8]. The latter constitutes a threat to recent gains in malaria control efforts, especially in Sub-Saharan Africa, where the majority of malaria cases occur. Fortunately, K13 mutations associated with artemisinin resistance have not yet been identified in Africa [8–10]. Since the implementation of ACT in DR Congo, most studies have reported ASAQ efficacy to be above the required threshold of 90% [6,11,12]. In one study conducted 10 years ago, PCR-corrected efficacy at day 28 was reported to be 85% in the Equator province [11]. However, the loose dose of ASAQ used in that study has a lower efficacy than the fixed dose [13].

This study describes malaria features in Kinshasa and assesses the efficacy of ASAQ after 42 days of treatment. In addition, it presents a cohort in which children who experienced clinical failures became eligible for inclusion in a randomized clinical trial (RCT) to assess the efficacy and safety of three rescue treatments, known as the Quinact study [14]. Furthermore, understanding of the diversity of malaria strains circulating and those involved in an infection episode can impact both treatment outcomes and the development of immunity in a community [15].

Materials and Methods

Trial design

This is a report on the first phase of the Quinact study in DR Congo, a bi-center, randomized, open label, 3-arm trial performed in three phases [14]. In DR Congo, the first phase consisted in treating eligible patients with ASAQ, the recommended drug for first-line treatment of uncomplicated malaria at the time the study was conceived. It was conducted at Lisungi Health Center in Kinshasa, the capital city of DR Congo.

Patients and treatment

We screened boys and girls aged between 12 and 59 months attending Lisungi Health Center for fever (tympanic temperature $\geq 38.0^{\circ}\text{C}$) or history of fever. Enrollment in the study was based on the following criteria: body weight ≥ 9 kg; microscopically confirmed mono-infection or mixed infection containing *Plasmodium falciparum* (parasitemia $\geq 2,000/\mu\text{l}$ to $200,000/\mu\text{l}$); hemoglobin (Hb) value ≥ 6.0 g/dl; signed (or thumb-printed and witnessed by an impartial witness if parents/guardians were illiterate) informed consent granted by the parents or guardians and parents' or guardians' willingness and ability to comply with the study protocol for the duration of the study. The body weight threshold of 9 kg was selected because the pre-qualified quinine used in the randomized phase was not available for children below this weight.

We excluded patients with severe malaria [16] or danger signs (not able to drink or breast-feed, vomiting more than twice in 24 hours, recent history of more than one convulsion in 24 hours, unconscious state, unable to sit or stand), known hypersensitivity and previous serious adverse events related to the study drugs, intercurrent illness, severe malnutrition, treatment with drugs which may prolong the QT interval (imidazole and triazole, antifungal agents), ongoing prophylaxis with drugs demonstrating antimalarial activity and those who had participated in any other investigational drug study during the previous 30 days.

ASAQ (Artesunate-amodiaquine Winthrop, Sanofi) was administered once daily over the course of three days. The tablets contained 50 mg of artesunate and 135 mg of amodiaquine for patients weighing 9 to 17.9 kg; and 100 mg of artesunate and 270 mg of amodiaquine for those weighing 18 to 35.9 kg. Treatment was observed directly by a study nurse. Patients were required to remain at the clinic for at least 60 minutes after drug intake. A full or half dose was repeated if vomiting occurred within 30 minutes or between 30 and 60 minutes of drug administration, respectively. If vomiting persisted, the patient was withdrawn from the study and referred to the health facility. The TREND checklist and the study protocol are available; see [S1 TREND Checklist](#), [S1 Protocol](#), and [S2 Protocol](#).

Follow up

After enrollment, patients were asked to attend the study site on the two following days for directly observed treatment in order to complete the 3-day course of ASAQ and then every two weeks until day 42. They were encouraged to attend the study site on any unscheduled day if they experienced any health problems. Adverse events (AEs) were documented at each visit. Follow-up was passive. Malaria infection was not screened systematically; this decision was made for logistical reasons, because the study team planned to implement standard active follow-up for the two subsequent phases [14]. Blood smears were only performed on day 42 and when patients were clinically suspected of having malaria during follow-up.

Blood samples were collected on filter paper (Whatman 3MM) on day 0 and on days when blood smears were performed, to enable subsequent parasite genotyping. Serum samples were

also collected upon recruitment and frozen for further immunological assessment (to be reported elsewhere).

Clinical assessment

Symptoms and physical examination findings were graded according to their severity (mild, moderate or severe) using the severity grading scale developed by the World Health Organization and the United States National Institute of Health, Division of Microbiology and Infectious Diseases.

Laboratory procedures and molecular interpretation

Thick and thin blood films were prepared, dried and stained with Giemsa 10% for 10 minutes. Thin smears were fixed with methanol before staining. Slides were examined using a light microscope at 1000 times magnification. The density of asexual parasites was determined on the basis of the number of parasites per 200 white blood cells (WBC), assuming a total WBC count of 8,000/ μ l. If fewer than 10 parasites were read per 200 WBC, the count was extended to 500 WBC. An independent double reading was performed, with the average taken as the final result. A third reader was required in the event of discrepancies. Hb was measured using a portable spectrophotometer (Hemocontrol, EKF Diagnostics, Barleben, Germany). The data management team based at the Infectious Diseases Institute, Makerere University in Uganda, produced a list of random slides to be sent periodically to the Institute of Tropical Medicine (ITM) in Antwerp, Belgium, for external quality control. In addition, two laboratory-specific monitoring visits were conducted by a lab technician from ITM's malaria unit.

PCR genotyping was performed at ITM, Antwerp, Belgium, to distinguish recrudescence from reinfection. DNA was extracted from dried blood spots using the QIAGEN QIAamp96 DNA blood kit. Each punch (5 mm) was eluted in 150 μ l of water. The blood spot samples taken from the malaria patients were characterized by the presence of one or more *Plasmodium* clones. Each clone was identified by a particular genotype defined by the alleles present at three loci, encoding GLURP (glutamate-rich protein), MSP (merozoite surface protein) 1 and MSP2, respectively.

In order to characterize the parasites in each blood spot, alleles from each locus were determined and interpreted as follows:

GLURP: alleles were characterized by size, differences in which were caused by varying numbers of a repeated unit.

MSP2: two sequence families (3D7 and FC27) were recognized at this locus, both of which varied in size because of different repeated numbers. In order to achieve the highest assay sensitivity, we used fluorochrome-labelled reverse primers that were specific either to the 3D7 or FC27 allelic family. Alleles were distinguished by their fluorescent dye (indicating the family) and by their size, which was determined using an automated sequencer.

MSP1: each allele was amplified using a PCR primer set specific to its sequence family (K1, MAD20 or Ro33).

If only one clone was present in a sample, then only one allele was found at each of the loci described above. If several clones were present, however, the number of alleles found at each locus could range between one and the number of clones. To determine whether it was a new infection or recrudescence that was causing clinical or parasitemic failure, we compared the genetic signatures of the samples at day 0 (D0) and day X (DX, at treatment failure). If at least one identical allele was found in these paired samples at each of the three loci, the failure was

classified as recrudescence. If only new alleles were observed at one or more loci at DX, the case was classified as a new infection. When the amplification reaction for one locus proved to be negative for either one or both of the paired samples, the outcome was classified as indeterminate. Outcomes were classified as protocol violations when *P. falciparum* was not identified in the samples collected at D0. All analyses, gel electrophoresis and data entries were double-checked by a second technician. GeneTools software version 4.03.05.0 (Synoptics Ltd, Cambridge, England) was used to score fragments of *GLURP* and *MSP1*, and GeneMapper version 4.1 (Applied Biosystems Inc., CA, USA) was used for *MSP2*.

The alleles recovered were binned according to allele size (base pairs, bp): 50 bp for *GLURP*; 3 bp for *MSP2*; and 25 bp for *MSP1*. The highly divergent alleles found at the *MSP2* locus were grouped into dimorphic families known as FC27 and 3D7. Likewise, the *MSP1* alleles were grouped into three families: K1, Mad20 and RO33. The stepwise genotyping strategy chosen for this study led to the genotyping of a different number of samples using each marker. In order to avoid bias due to repeated counts of alleles within one patient with multiple infections, the basal level of allelic patterns and genetic diversity was initially assessed using D0 samples only.

We then calculated and compared the allelic patterns and level of genetic diversity described by each marker between the baseline (D0) and recurrent infections (DX), where N_a = number of alleles, N_a frequency $\geq 5\%$ = alleles found with a frequency $\geq 5\%$ and H_e = expected heterozygosity, i.e. a measure of the degree of polymorphism in each marker. The infections were classified as baseline samples (D0) or recurrent infections (DX) and then according to the number of *P. falciparum*-carrying clones: monoclonal (1 allele per locus) or polyclonal infection (≥ 2 alleles in at least one locus). Multiplicity of infection (MOI, minimal number of distinct haplotypes or "strains" within a sample) was estimated using the locus with the highest number of alleles as a proxy [17].

Sample size and data analysis

The sample size was calculated on the basis of the randomized phase of the Quinact trial (reported separately). Recruitment in the first phase was to be continued until the number of failures required for the RCT phase was reached [14]. Data were handled using the DataFax system (Clinical DataFax Systems Inc., Ontario, Canada), in collaboration with the Infectious Diseases Institute, Makerere University, Uganda, where the database was located. Stata software version 12 (Stata Corp, Lakeway, College Station, Texas, USA) was used for the analyses.

Frequencies, percentages, means and medians were obtained using descriptive statistics. The association between MOI and treatment failure was determined with Kaplan Meier survival analysis and a Cox proportional hazard model adjusted for age, D0 parasite density, Hb concentration and temperature. The proportions of polyclonal infections at D0 and DX were compared using a Pearson χ^2 test and average MOIs compared using the Mann-Whitney U test. The allelic patterns—number of alleles and private alleles (alleles unique to a single group, i.e. D0 or DX) and level of genetic diversity (H_e = expected heterozygosity, ranges from 0 to 1, from no diversity to highly diverse)—were calculated using GenAlix v.6.5 [18,19]. The odds of having a polyclonal infection were evaluated by means of a logistic regression controlling for age, parasite density, Hb concentration and presence of fever in D0 infections. Estimates of risks were based on survival analysis approaches, in which events were defined as recrudescence and data were censored for new infections and the end of observation. The curves compared the risk of encountering PCR-corrected treatment failure when either a monoclonal (MOI = 1) or polyclonal (MOI ≥ 2) infection was observed at D0.

The primary outcome was adequate clinical and parasitological response (ACPR) at day 42, as the passive form of follow-up used in this study phase did not allow us to establish treatment outcomes according to the standard WHO classification [20]. We considered late treatment failure to be any failure occurring from day 14 onwards, as this was the threshold for recruitment in the RCT phase. ASAQ efficacy was assessed using per-protocol analysis. Patients with indeterminate results and/or protocol violations were not taken into account when adjusting treatment efficacy to PCR.

Ethical approval

The study protocol was approved by the ethical committees of the University of Antwerp (Reference: UA-A11-02) and the School of Public Health, University of Kinshasa (Reference: ESP/CE/012B/2012). Parents or guardians were asked to sign (or thumb-print if they were illiterate) informed consent forms. The study was externally monitored by the Amsterdam Institute for Global Health and Development in order to guarantee the quality of the data. The study team complied with good clinical and laboratory practice requirements. The protocol was registered under the references NCT01374581 and PACTR201203000351114 in ClinTrials.gov and in the Pan African Clinical Trials Registry, respectively.

Results

Trial profile and baseline characteristics

A total of 2796 patients were screened for eligibility in the first phase of the Quinact trial between August 2012 and January 2014. Of these, 145 patients (5.2%) were excluded on clinical bases. Subsequently, 2651 patients (94.8%) were tested for malaria; more than half tested negative (52.8%). In total, 865 patients fulfilled the selection criteria and were treated with ASAQ. At recruitment, the mean age was 36.2 months (SD: 13.2) and mean Hb was 9.3 g/dl (SD: 1.6). Approximately one third of patients (34.8%) had slept under a mosquito net the night before enrollment (Table 1). Those who had not slept under a mosquito net were considered to be at greater risk of recurrent malaria ($p < 0.001$). During follow-up, 95/865 patients (11.0%) were excluded from the study due to persisting vomiting ($n = 10$), serious adverse events (SAEs) ($n = 3$), loss to follow-up ($n = 71$), withdrawal of informed consent ($n = 6$) or intake of

Table 1. Demographic and baseline clinical characteristics of study participants receiving ASAQ treatment at Lisungi Health Center, Kinshasa, DR Congo.

Characteristic	ASAQ n = 865
Age (months, mean (SD))	36.2 (13.2)
Male (n (%))	442 (51.1)
Weight (kg, median (IQR))	12.5 (11.0–14.7)
Height (cm, median (IQR))	91.0 (82.9–99.5)
Slept under mosquito net the previous night (yes, n (%))	301 (34.8)
Tympanic temperature (°C, median (IQR))	37.6 (37.1–38.4)
Temperature $\geq 38^\circ\text{C}$ (yes, n (%))	319 (37.0)
Hemoglobin concentration (g/dl, mean (SD))	9.3 (1.6)
Asexual parasites/ μl (geometric mean (95%CI))	23,007 (21,047–25,149)
Gametocyte carriage (yes, n (%))	19 (2.2)
Sick in the last two months (yes, n (%))	495 (57.2)

SD, standard deviation; IQR, interquartile range; CI, confidence interval

doi:10.1371/journal.pone.0157074.t001




Fig 1. Trial profile of 42 days of passive follow-up after ASAQ treatment in Lisungi, Kinshasa, DR Congo.

doi:10.1371/journal.pone.0157074.g001

prohibited medication (n = 5) (Fig 1). SAEs consisted of hospitalizations and one case resulted in death, but none of these events were judged by the investigators to be related to ASAQ intake. Ultimately, 770 patients (89.0%) completed follow-up and were included in the analyses. Patients who did not complete follow-up had comparable baseline characteristics to the per protocol group.

Medical history

The parents/guardians of 495 patients (57.2%) reported that their child had been sick in the last two months, but information about the condition was provided in only 106 (21.4%) of these cases. The most frequently reported condition was malaria, including co-morbidities (58.5%). Fever not clearly related to disease was reported by 41 (38.7%) parents/guardians. The parents/guardians of 278 patients were able to describe individual treatment courses prescribed during the month before enrollment. These had either been prescribed at health facilities or represented self-medication. The most common medication class that participants had received in the month before enrollment was antipyretics (44.2%), followed by antimalarial drugs (15.1%) and antibiotics (8.6%).

Clinical and biological features

All participants exhibited fever and/or history of fever, and this was the key symptom for screening. The most frequent symptoms were weakness, cough, behavioral changes and coryza. Jaundice and dehydration were rare, but chest examinations revealed abnormal results in 78% of patients (Table 2). Parasite density tended to diminish in older children (Fig 2).

Allelic patterns and genetic diversity

The three markers showed high levels of polymorphism (*He*: 0.90–0.97). MSP2 was found to be the most polymorphic, exhibiting up to 114 different alleles (only two alleles with a frequency of above 5%), while 20 and 19 alleles (35% and 47.4% of total alleles with a frequency above 5%) were discovered for MSP1 and GLURP, respectively (Table 3). The levels of genetic diversity (*He*) of the three markers did not change among baseline samples (D0) or recurrence after treatment (DX). MSP2 revealed the largest number of private alleles in D0 and DX (26.3% and 17.5%), followed by MSP1 (15.0% and 19.0%) and GLURP (5.3% in both) (Table 3). The proportion of private alleles in the total number of alleles for each case is indicated between parentheses.

Within-host parasite diversity, multiplicity of infection (MOI) and risk of recrudescence

The majority of infections (78.8% of 146) contained a mixture of MSP2 family-specific alleles (3D7 and FC27), while only 13.7% and 7.5% exhibited parasites carrying only alleles

Table 2. Baseline symptoms and signs before 42-day passive follow-up after ASAQ treatment in Lisungi, Kinshasa, DR Congo (865 patients).

	Absent	Mild	Moderate	Severe
Fever in the last 24 hours	-	-	865 (100)	-
Weakness	349 (40.4)	263 (30.4)	249 (28.7)	4 (0.5)
Vomiting	563 (65.1)	158 (18.3)	144 (16.6)	-
Allergic reaction	849 (98.2)	1 (0.1)	15 (1.7)	-
Diarrhea	709 (82.0)	134 (15.5)	22 (2.5)	-
Cough	399 (46.1)	275 (31.8)	157 (18.2)	34 (3.9)
Pruritus	683 (78.9)	90 (10.4)	89 (10.3)	3 (0.4)
Behavioral changes	320 (37.0)	293 (33.9)	251 (29.0)	1 (0.1)
Convulsion	861 (99.5)	-	-	4 (0.5)
Coryza	347 (40.1)	246 (28.4)	272 (31.5)	-
Muscle and joint pain*	371 (87.3)	24 (5.7)	30 (7.0)	-
Headache*	256 (60.2)	66 (15.5)	103 (24.3)	-
Nausea*	403 (94.8)	21 (4.9)	1 (0.3)	-
Dizziness*	416 (97.9)	8 (1.9)	1 (0.2)	-
Abdominal pain*	190 (44.7)	107 (25.2)	126 (29.6)	2 (0.5)
Tinnitus*	419 (98.6)	2 (0.5)	4 (0.9)	-
Jaundice	828 (95.7)	37 (4.3)	-	NA
Dehydration	848 (98.0)	14 (1.6)	3 (0.4)	NA
	Normal	Abnormal		
Chest examination	190 (22.0)	675 (78.0)	-	-
Abdominal examination**	568 (65.8)	295 (34.2)	-	-
Skin examination	668 (77.1)	197 (22.9)	-	-

NA, not applicable

*applicable only for children > 36 months old (n = 425)

**out of 863 (not performed for two patients)

doi:10.1371/journal.pone.0157074.t002




Fig 2. Fitted line plot of parasite density (P/ µl) according to age (months) among children under the age of five (shaded area is 95%CI).

doi:10.1371/journal.pone.0157074.g002

3D7 or FC27, respectively. Similarly, most infections contained a mixture of MSP1 family-specific alleles (79.7% of 64); and infections containing alleles from all three MSP1 allelic families reached 40%. Among infections containing parasites carrying only one MSP1 allelic family, K1 alleles were found to be more frequent (17.2%) than Mad20 and RO33 (1.6% in both cases) (Fig 3). Multiplicity of infection was not associated with parasite density (OR = 1.0, 95%CI:

Table 3. Allelic patterns and genetic diversity of *P. falciparum* in baseline and recurrent infections.

Marker		GLURP	MSP2			MSP1			
			3D7	FC27	overall MSP2	K1	Mad20	RO33	overall MSP1
Allelic family	D0	338	135	126	146	60	43	37	64
	DX	334	124	114	146	60	33	41	65
Allele range (bp)	overall	584–1564	168–618	91–639		140–389	126–362	199–256	
Number of alleles detected	D0	929	344	217	561	187	64	43	294
	DX	787	263	201	464	144	52	41	237
Na frequency ≥5%	D0	19 (9)	88 (1)	26 (5)	114 (2)	11 (7)	6 (5)	3 (3)	20 (7)
	DX	19 (7)	75 (0)	29 (5)	104 (3)	10 (6)	10 (6)	1 (1)	21 (7)
Number of private alleles	D0	1 (5.3%)	21	9	30 (26.3%)	1	0	2	3 (15.0%)
	DX	1 (5.3%)	8	12	20 (17.5%)	0	4	0	4 (19.0%)
<i>He</i>	D0	0.91	0.98	0.86	0.97	0.86	0.74	0.26	0.91
	DX	0.89	0.98	0.87	0.97	0.85	0.79	0.00	0.90

D0, day of recruitment; DX, day of treatment failure; bp, base pairs; Na, number of alleles; He, level of genetic diversity

doi:10.1371/journal.pone.0157074.t003




Fig 3. Distribution of the allelic families of MSP2 (3D7 and FC27) and MSP1 within baseline infections.

doi:10.1371/journal.pone.0157074.g003

0.99–1.00), age (OR: 0.99, 95%CI: 0.97–1.02) or Hb (OR: 1.06, 95%CI: 0.85–1.31), but did appear to be associated with fever (OR: 3.10, 95%CI: 1.83–17.52).

In total, 64 and 146 samples (both monoclonal and polyclonal) were genotyped using MSP1 and MSP2, respectively. The infections contained alleles belonging either to a single allelic family or to two or three different families. Multiple alleles belonging to the same family were found within one infection. Polyclonal infections were more frequent at D0 and DX (88.1% and 80.1%, respectively) than were monoclonal infections ($p = 0.005$). The median MOI found in recurrence samples (MOI = 3; IQR: 1–5) was lower than the MOI found in D0 samples (MOI = 3.7; IQR: 0.7–6.7) ($p < 0.001$). The odds of having a polyclonal infection were 1.8 times higher (95%CI: 1.20–2.8) for pre-treatment samples than for recurrences. Among patients with treatment failure, those with new infections were found to be carrying up to 10 haplotypes, while those with recrudescence were harboring up to 14 haplotypes (Fig 4).

No risk of recrudescence was found when the D0 infection was monoclonal (Fig 5), while polyclonal infection was related to a recrudescence risk of 19.2% ($p = 0.002$). Similarly, the Cox




Fig 4. Frequency of MOI in new infections and recrudescences after ASAQ treatment failure.

doi:10.1371/journal.pone.0157074.g004




Fig 5. Multiplicity of infection in D0 infections and risk of recrudescence after 42 days of follow-up.

doi:10.1371/journal.pone.0157074.g005

hazard model states that the risk of treatment failure increases by 28% for each additional *P. falciparum* haplotype found within the D0 infection (HR: 1.3, 95%CI: 1.24–1.44, $p < 0.001$).

Treatment outcome

No clinical failure occurred before day 14. Forty-five percent of patients experienced treatment failure during the 42-day follow-up period (Table 4). PCR-corrected results revealed that 83.6% (95%CI: 79.1–87.2) of patients had a new infection. ASAQ efficacy after PCR adjustment was 92.8% (95%CI: 91.0–94.6). PCR confirmed that two participants had dual infections, including *P. ovale*, at recruitment, but neither of them experienced *P. ovale*-related recurrence.

Table 4. ASAQ treatment outcomes during passive follow-up in Lisungi, Kinshasa, DR Congo (770 patients).

	PCR uncorrected n/N (%)	PCR corrected n/N (%)
Early clinical failure	0	-
Late clinical failure	290/770 (37.7)	-
Late parasitological failure	54/770 (7.00)	-
Total failure	344/770 (44.7)	-
New infections	-	281/336 (83.6)
Recrudescence	-	55/336 (16.4)
Indeterminate	-	7
Protocol violations*	-	1
ACPR	426/770 (55.3)	707/762 (92.8)

ACPR, adequate clinical and parasitological response

*PCR revealed that this patient had a *P. malariae* and *P. ovale* mixed infection at recruitment and *P. falciparum* at failure.

doi:10.1371/journal.pone.0157074.t004

Discussion

This study highlights the clinical and molecular features of malaria in Kinshasa, DR Congo, and provides up-to-date data on ASAQ efficacy when treating uncomplicated malaria in children under five years of age. Malaria is clinically characterized by non-specific symptoms which may mimic flu-like syndromes and even lead to misdiagnosis of gastrointestinal infection [21]. Sixty percent and 54% of our study participants presented with coryza and cough, respectively, a finding which underscores the relationship between parasitemia and non-specific symptoms. Considering the prevalence of asymptomatic malaria infection—up to 30.9% around the study site [22]—it is likely that many patients attend the hospital when another cause of fever arises and that this contributes to the appearance of asymptomatic *Plasmodium* infection. In Nigeria, upper respiratory tract infections have been reported in 70% of patients testing positive for malaria in an outpatient department [23].

Furthermore, more research is needed to explore the causes of fever in the study area; a study conducted by D'Acremont *et al* in Tanzania, for example, has succeeded in revealing causes of fever beyond malaria [24]. However, malaria should be treated whenever the *Plasmodium* infection is confirmed, and co-morbidities should be managed accordingly. Our data suggest that parasite density tends to decrease as age increases (Fig 2), most likely as a result of developing immunity.

The proportion of patients with ACPR at day 42 was 92.8% after PCR adjustment. However, the proportion of recurrent malaria was high, at 44.7%. Onyamboko *et al* have already reported a similar finding in Kinshasa, namely a PCR-corrected ACPR of 93.7%, but accompanied by a much lower level of recurrent infections (27%) [6]. This discrepancy indicates that malaria features may be heterogeneous in one area, as highlighted by Mvumbi *et al* [25]. The relatively high number of recurrent malaria observed in this study could be attributed to various factors. One is the higher number of strains that were involved, which may have led to slower development of immunity in the study population, as suggested by Branch *et al* [26]. Another possible factor is the poor prophylactic effect of amodiaquine. In combination treatment for malaria, the artemisinin derivative is intended to clear the parasites quickly, as demonstrated by the lack of early treatment failures. The partner drug, which has a longer half-life, is expected to clear the remaining parasites and offer protection against new infections. We refer only to amodiaquine here, because mutations conferring resistance to artemisinin have not yet been identified in Africa [8–10]. The level of resistance to amodiaquine may be increasing, and affecting its prophylactic effect. Yet, two previous studies were unable to report concerns about amodiaquine resistance [27,28]. It is essential that resistance to amodiaquine, and other anti-malarial drugs, be monitored on a regular basis. Levels of malaria transmission may also have played a role. Roughly half of our patients tested positive for malaria: a much higher proportion than the 20% reported by Muhindo *et al* [29]. The latter was an average for the city of Kinshasa as a whole, however, while almost all of the patients screened in our study were living in one particular area. Nonetheless, entomological studies are still needed to assess the level of malaria transmission. Furthermore, poor utilization of mosquito nets increases the risk of malaria recurrence. Host susceptibility could also be a factor explaining the relatively high proportion of recurrent malaria found in our study, but immunological assessment is needed.

In general, the patients screened in our study proved to be infected by a high number of *P. falciparum* strains. Children under five years of age carry the majority of the strains in circulation because of their vulnerability to malaria infection [15]. The results presented here are likely to reflect the reality of *P. falciparum* diversity in the study area and therefore represent baseline knowledge of the diversity and multiplicity of infection in Kinshasa. In addition, most malaria cases identified in this study were polyclonal infections. Some studies have

demonstrated a positive association between high *P. falciparum* diversity and MOI, on the one hand, and high malaria transmission, on the other [30–33], though this association was not found in Papua New Guinea [34].

The odds of having a polyclonal infection were lower among recurrences than at enrollment. In order to reinforce this trend, which probably reflects the impact of effective medication; joint strategies for malaria prevention (e.g. insecticide-treated mosquito nets, intermittent preventive treatment and malaria vaccines) are needed to reduce multiple-strain infections [15]. However, the impact of these strategies on *P. falciparum* diversity is not entirely clear. Yet, even in areas where malaria incidence has decreased by 90%, no decrease in parasite diversity has been documented [35]. This study shows that MOI impacts the subsequent risk of recrudescence. Indeed, the risk of recrudescence actually increases along with the number of haplotypes involved in the initial episode. This finding is in line with reports from Uganda [15,36]. While theoretically possible, it is extremely unlikely that patients classified by PCR as having recrudescence infections had been re-infected by the same strains [37]. In contrast to the study by Kyabayinze *et al* [15], we found that patients presenting with fever at recruitment (tympanic temperature $\geq 38^{\circ}\text{C}$) were more likely to be infected by more than one haplotype.

The passive form of follow-up used in this study is likely to have had an impact on the estimation of the proportion of recurrent infections. If the standard procedures for antimalarial efficacy follow-up were applied in the study—with systematic malaria screening on days 1, 2, 3, 7, 14, 21, 28, 35 and 42 [20]—the study site could have been overloaded. As a result, the study team avoided active follow-up in order to maintain the quality of the data generated. Despite the limitations of the study design chosen, it did allow us to update estimates of ASAQ efficacy in Kinshasa. In addition, it provided some insight into the diversity of malaria parasites, in line with the Plasmodium Diversity Network Africa targets [38].

Conclusions

ASAQ remains a suitable treatment for uncomplicated malaria in Kinshasa, with a PCR-corrected efficacy of 92.8% after 42 days of follow-up. The proportion of crude treatment failures was relatively high in this study, perhaps because of the poor prophylactic effect of amodiaquine, the high level of malaria transmission or the high host susceptibility to malaria among children participating in the study. Infection with a single haplotype of *P. falciparum* was found to predict a positive treatment outcome. Therefore, reducing the diversity of circulating *P. falciparum* may be key to slowing down the spread of resistant strains.

This study emphasizes the need for further research on *in vitro* amodiaquine resistance profiles and the consequences of MOI on treatment efficacy, malaria transmission and immunity development; and entomological studies for assessing malaria transmission levels. *In vivo* efficacy studies of ACTs are also of paramount importance.

Supporting Information

S1 TREND Checklist.

(PDF)

S1 Protocol. Quinact protocol published in Trials Journal.

(PDF)

S2 Protocol. Quinact protocol.

(PDF)

Acknowledgments

The authors would like to thank the parents of the children enrolled in this study as well as the study staff (Georgette Ndelela, Florence Namazu, Noella Kabamba, Olivier Kaniki, Ezechias Mumbenga, John Milambu, Bibiche Ekoko, Nancy Mwema, Bibi Umba, Bienvenu Mbuku and Jeanne Badimuena). Many thanks to Sanofi for the kind donation of artesunate-amodiaquine and Quinine used in the Quinact trial. The constructive monitoring provided by the Amsterdam Institute of Global Health Development was greatly appreciated. Our compliments to Vito Baraka for the kind proofreading of the manuscript. Linguapolis, the language support unit of the University of Antwerp, provided editorial review.

Author Contributions

Conceived and designed the experiments: HMM PL JPVg. Performed the experiments: HMM MK BF RIDL PL. Analyzed the data: HMM CDR VM JPVg. Contributed reagents/materials/analysis tools: RM ARU. Wrote the paper: HMM JPVg CDR VM MK RIDL ARU PL BF RM.

References

1. WHO. World malaria report 2013. Switzerland: World Health Organization, 2014 Mar 20.
2. PNL. Rapport annuel des activités de lutte contre le Paludisme. Kinshasa: Programme National de Lutte contre le Paludisme, Ministère de la Santé Publique, République Démocratique du Congo, 2014.
3. Zwang J, Dorsey G, Martensson A, D'Alessandro U, Ndiaye JL, Karema C, et al. Plasmodium falciparum clearance in clinical studies of artesunate-amodiaquine and comparator treatments in sub-Saharan Africa, 1999–2009. *Malar J.* 2014; 13:114. doi: [10.1186/1475-2875-13-114](https://doi.org/10.1186/1475-2875-13-114) PMID: [24666562](https://pubmed.ncbi.nlm.nih.gov/24666562/)
4. Adjuik M, Babiker A, Garner P, Olliaro P, Taylor W, White N. Artesunate combinations for treatment of malaria: meta-analysis. *Lancet.* 2004 Jan 3; 363(9402):9–17. PMID: [14723987](https://pubmed.ncbi.nlm.nih.gov/14723987/)
5. PNL. Directives nationales de traitement du paludisme en République Démocratique du Congo. Kinshasa: Programme National de Lutte contre le Paludisme, Ministère de la Santé Publique, République Démocratique du Congo. 2010.
6. Onyamboko MA, Fanello CI, Wongsan K, Tarning J, Cheah PY, Tshefu KA, et al. Randomized comparison of the efficacies and tolerabilities of three artemisinin-based combination treatments for children with acute Plasmodium falciparum malaria in the Democratic Republic of the Congo. *Antimicrob Agents Chemother.* 2014 Sep; 58(9):5528–36. doi: [10.1128/AAC.02682-14](https://doi.org/10.1128/AAC.02682-14) PMID: [25001306](https://pubmed.ncbi.nlm.nih.gov/25001306/)
7. Arie F, Witkowski B, Amaratunga C, Beghain J, Langlois AC, Khim N, et al. A molecular marker of artemisinin-resistant Plasmodium falciparum malaria. *Nature.* 2014 Jan 2; 505(7481):50–5. doi: [10.1038/nature12876](https://doi.org/10.1038/nature12876) PMID: [24352242](https://pubmed.ncbi.nlm.nih.gov/24352242/)
8. Ashley EA, Dhorda M, Fairhurst RM, Amaratunga C, Lim P, Suon S, et al. Spread of artemisinin resistance in Plasmodium falciparum malaria. *N Engl J Med.* 2014 Jul 31; 371(5):411–23. doi: [10.1056/NEJMoa1314981](https://doi.org/10.1056/NEJMoa1314981) PMID: [25075834](https://pubmed.ncbi.nlm.nih.gov/25075834/)
9. Kamau E, Campino S, Amenga-Etego L, Drury E, Ishengoma D, Johnson K, et al. K13-Propeller Polymorphisms in Plasmodium falciparum Parasites From Sub-Saharan Africa. *J Infect Dis.* 2015 Apr 15; 211(8):1352–5. doi: [10.1093/infdis/jiu608](https://doi.org/10.1093/infdis/jiu608) PMID: [25367300](https://pubmed.ncbi.nlm.nih.gov/25367300/)
10. Taylor SM, Parobek CM, DeConti DK, Kayentao K, Coulibaly SO, Greenwood BM, et al. Absence of putative artemisinin resistance mutations among Plasmodium falciparum in Sub-Saharan Africa: a molecular epidemiologic study. *J Infect Dis.* 2015 Mar 1; 211(5):680–8. doi: [10.1093/infdis/jiu467](https://doi.org/10.1093/infdis/jiu467) PMID: [25180240](https://pubmed.ncbi.nlm.nih.gov/25180240/)
11. Bonnet M, Broek I, van HM, Urrutia PP, Van OC, Kyomuhendo J, et al. Varying efficacy of artesunate + amodiaquine and artesunate + sulphadoxine-pyrimethamine for the treatment of uncomplicated falciparum malaria in the Democratic Republic of Congo: a report of two in-vivo studies. *Malar J.* 2009; 8:192. doi: [10.1186/1475-2875-8-192](https://doi.org/10.1186/1475-2875-8-192) PMID: [19664280](https://pubmed.ncbi.nlm.nih.gov/19664280/)
12. Espie E, Lima A, Atua B, Dhorda M, Flevaud L, Sompwe EM, et al. Efficacy of fixed-dose combination artesunate-amodiaquine versus artemether-lumefantrine for uncomplicated childhood Plasmodium falciparum malaria in Democratic Republic of Congo: a randomized non-inferiority trial. *Malar J.* 2012; 11:174. doi: [10.1186/1475-2875-11-174](https://doi.org/10.1186/1475-2875-11-174) PMID: [22631564](https://pubmed.ncbi.nlm.nih.gov/22631564/)
13. The effect of dosing strategies on the therapeutic efficacy of artesunate-amodiaquine for uncomplicated malaria: a meta-analysis of individual patient data. *BMC Med.* 2015; 13:66. doi: [10.1186/s12916-015-0301-z](https://doi.org/10.1186/s12916-015-0301-z) PMID: [25888957](https://pubmed.ncbi.nlm.nih.gov/25888957/)

14. Muhindo MH, Nabasumba C, Tinto H, D'Alessandro U, Grobusch MP, Lutumba P, et al. Impact of retreatment with an artemisinin-based combination on malaria incidence and its potential selection of resistant strains: study protocol for a randomized controlled clinical trial. *Trials*. 2013; 14:307. doi: [10.1186/1745-6215-14-307](https://doi.org/10.1186/1745-6215-14-307) PMID: [24059911](https://pubmed.ncbi.nlm.nih.gov/24059911/)
15. Kyabayinze DJ, Karamagi C, Kiggundu M, Kanya MR, Wabwire-Mangen F, Kironde F, et al. Multiplicity of *Plasmodium falciparum* infection predicts antimalarial treatment outcome in Ugandan children. *Afr Health Sci*. 2008 Dec; 8(4):200–5. PMID: [20589125](https://pubmed.ncbi.nlm.nih.gov/20589125/)
16. Severe falciparum malaria. World Health Organization, Communicable Diseases Cluster. *Trans R Soc Trop Med Hyg*. 2000 Apr; 94 Suppl 1:S1–90. PMID: [11103309](https://pubmed.ncbi.nlm.nih.gov/11103309/)
17. Delgado-Ratto C, Soto-Calle VE, Van den Eede P, Gamboa D, Rosas A, Abatih EN, et al. Population structure and spatio-temporal transmission dynamics of *Plasmodium vivax* after radical cure treatment in a rural village of the Peruvian Amazon. *Malar J*. 2014; 13:8. doi: [10.1186/1475-2875-13-8](https://doi.org/10.1186/1475-2875-13-8) PMID: [24393454](https://pubmed.ncbi.nlm.nih.gov/24393454/)
18. Peakall R, Smouse PE. GenAIEx 6.5: genetic analysis in Excel. Population genetic software for teaching and research—an update. *Bioinformatics*. 2012 Oct 1; 28(19):2537–9. PMID: [22820204](https://pubmed.ncbi.nlm.nih.gov/22820204/)
19. Peakall R, Smouse P. genalex 6: genetic analysis in Excel. Population genetic software for teaching and research. *Molecular Ecology Notes* 6, 288–295. 2006.
20. WHO. Assessment and monitoring of antimalarial drug efficacy for the treatment of uncomplicated falciparum malaria. Switzerland: World Health Organization. 2003.
21. Bartoloni A, Zammarchi L. Clinical aspects of uncomplicated and severe malaria. *Mediterr J Hematol Infect Dis*. 2012; 4(1):e2012026. doi: [10.4084/MJHID.2012.026](https://doi.org/10.4084/MJHID.2012.026) PMID: [22708041](https://pubmed.ncbi.nlm.nih.gov/22708041/)
22. Maketa V, Mavoko HM, da Luz RI, Zanga J, Lubiba J, Kalonji A, et al. The relationship between *Plasmodium* infection, anaemia and nutritional status in asymptomatic children aged under five years living in stable transmission zones in Kinshasa, Democratic Republic of Congo. *Malar J*. 2015; 14:83. doi: [10.1186/s12936-015-0595-5](https://doi.org/10.1186/s12936-015-0595-5) PMID: [25880427](https://pubmed.ncbi.nlm.nih.gov/25880427/)
23. Etiaba E, Onwujekwe O, Uzochukwu B, Uguru N, Okoronkwo I, Adjagba A. What co-morbidities do people with malaria have and what are their patterns of health seeking in Nigeria? *Niger J Clin Pract*. 2015 Jan; 18(1):22–6. doi: [10.4103/1119-3077.146974](https://doi.org/10.4103/1119-3077.146974) PMID: [25511339](https://pubmed.ncbi.nlm.nih.gov/25511339/)
24. D'Acremont V, Kilowoko M, Kyungu E, Philipina S, Sangu W, Kahama-Marro J, et al. Beyond malaria—causes of fever in outpatient Tanzanian children. *N Engl J Med*. 2014 Feb 27; 370(9):809–17. doi: [10.1056/NEJMoa1214482](https://doi.org/10.1056/NEJMoa1214482) PMID: [24571753](https://pubmed.ncbi.nlm.nih.gov/24571753/)
25. Mvumbi DM, Kayembe JM, Situakibanza H, Bobanga TL, Nsibu CN, Mvumbi GL, et al. Falciparum malaria molecular drug resistance in the Democratic Republic of Congo: a systematic review. *Malar J*. 2015; 14(1):354.
26. Branch OH, Takala S, Kariuki S, Nahlen BL, Kolczak M, Hawley W, et al. *Plasmodium falciparum* genotypes, low complexity of infection, and resistance to subsequent malaria in participants in the Asembo Bay Cohort Project. *Infect Immun*. 2001 Dec; 69(12):7783–92. PMID: [11705960](https://pubmed.ncbi.nlm.nih.gov/11705960/)
27. Mvumbi DM, Boreux R, Sacheli R, Lelo M, Lengu B, Nani-Tuma S, et al. Assessment of pfcrt 72–76 haplotypes eight years after chloroquine withdrawal in Kinshasa, Democratic Republic of Congo. *Malar J*. 2013; 12:459. doi: [10.1186/1475-2875-12-459](https://doi.org/10.1186/1475-2875-12-459) PMID: [24359280](https://pubmed.ncbi.nlm.nih.gov/24359280/)
28. Antonia AL, Taylor SM, Janko M, Emch M, Tshetu AK, Meshnick SR. A cross-sectional survey of *Plasmodium falciparum* pfcrt mutant haplotypes in the Democratic Republic of Congo. *Am J Trop Med Hyg*. 2014 Jun; 90(6):1094–7. doi: [10.4269/ajtmh.13-0378](https://doi.org/10.4269/ajtmh.13-0378) PMID: [24732459](https://pubmed.ncbi.nlm.nih.gov/24732459/)
29. Muhindo HM, Ilombe G, Meya R, Mitashi PM, Kutekemeni A, Gasigwa D, et al. Accuracy of malaria rapid diagnosis test Optimal-IT((R)) in Kinshasa, the Democratic Republic of Congo. *Malar J*. 2012; 11:224. doi: [10.1186/1475-2875-11-224](https://doi.org/10.1186/1475-2875-11-224) PMID: [22770130](https://pubmed.ncbi.nlm.nih.gov/22770130/)
30. Arnot D. Unstable malaria in Sudan: the influence of the dry season. Clone multiplicity of *Plasmodium falciparum* infections in individuals exposed to variable levels of disease transmission. *Trans R Soc Trop Med Hyg*. 1998 Nov; 92(6):580–5. PMID: [10326095](https://pubmed.ncbi.nlm.nih.gov/10326095/)
31. Arnot DE. The influence of the genetic complexity of *Plasmodium falciparum* infections on the epidemiology of malaria. *Trans R Soc Trop Med Hyg*. 2002 Apr; 96 Suppl 1:S131–S136. PMID: [12055826](https://pubmed.ncbi.nlm.nih.gov/12055826/)
32. Talisuna AO, Langi P, Bakyaite N, Egwang T, Mutabingwa TK, Watkins W, et al. Intensity of malaria transmission, antimalarial-drug use and resistance in Uganda: what is the relationship between these three factors? *Trans R Soc Trop Med Hyg*. 2002 May; 96(3):310–7. PMID: [12174786](https://pubmed.ncbi.nlm.nih.gov/12174786/)
33. Kiwanuka GN. Genetic diversity in *Plasmodium falciparum* merozoite surface protein 1 and 2 coding genes and its implications in malaria epidemiology: a review of published studies from 1997–2007. *J Vector Borne Dis*. 2009 Mar; 46(1):1–12. PMID: [19326702](https://pubmed.ncbi.nlm.nih.gov/19326702/)

34. Barry AE, Schultz L, Senn N, Nale J, Kiniboro B, Siba PM, et al. High levels of genetic diversity of *Plasmodium falciparum* populations in Papua New Guinea despite variable infection prevalence. *Am J Trop Med Hyg.* 2013 Apr; 88(4):718–25. doi: [10.4269/ajtmh.12-0056](https://doi.org/10.4269/ajtmh.12-0056) PMID: [23400571](https://pubmed.ncbi.nlm.nih.gov/23400571/)
35. Kariuki SK, Njunge J, Muia A, Muluvi G, Gatei W, Ter KF, et al. Effect of malaria transmission reduction by insecticide-treated bed nets (ITNs) on the genetic diversity of *Plasmodium falciparum* merozoite surface protein (MSP-1) and circumsporozoite (CSP) in western Kenya. *Malar J.* 2013; 12:295. doi: [10.1186/1475-2875-12-295](https://doi.org/10.1186/1475-2875-12-295) PMID: [23978002](https://pubmed.ncbi.nlm.nih.gov/23978002/)
36. Lee SA, Yeka A, Nsoya SL, Dokomajilar C, Rosenthal PJ, Talisuna A, et al. Complexity of *Plasmodium falciparum* infections and antimalarial drug efficacy at 7 sites in Uganda. *J Infect Dis.* 2006 Apr 15; 193(8):1160–3. PMID: [16544257](https://pubmed.ncbi.nlm.nih.gov/16544257/)
37. McKenzie FE, Smith DL, O'Meara WP, Riley EM. Strain theory of malaria: the first 50 years. *Adv Parasitol.* 2008; 66:1–46. doi: [10.1016/S0065-308X\(08\)00201-7](https://doi.org/10.1016/S0065-308X(08)00201-7) PMID: [18486688](https://pubmed.ncbi.nlm.nih.gov/18486688/)
38. Ghansah A, Amenga-Etego L, Amambua-Ngwa A, Andagalu B, Apinjoh T, Bouyou-Akotet M, et al. Monitoring parasite diversity for malaria elimination in sub-Saharan Africa. *Science.* 2014 Sep 12; 345(6202):1297–8. doi: [10.1126/science.1259423](https://doi.org/10.1126/science.1259423) PMID: [25214619](https://pubmed.ncbi.nlm.nih.gov/25214619/)